3-Hydroxysteroid Dehydrogenases
"3-Hydroxysteroid Dehydrogenases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Catalyze the oxidation of 3-hydroxysteroids to 3-ketosteroids.
| Descriptor ID |
D015096
|
| MeSH Number(s) |
D08.811.682.047.436.350
|
| Concept/Terms |
3-Hydroxysteroid Dehydrogenases- 3-Hydroxysteroid Dehydrogenases
- Dehydrogenases, 3-Hydroxysteroid
- 3-beta-Hydroxysteroid Dehydrogenase
- 3 beta Hydroxysteroid Dehydrogenase
- Dehydrogenase, 3-beta-Hydroxysteroid
- 3 Hydroxysteroid Dehydrogenases
- Dehydrogenases, 3 Hydroxysteroid
- Hydroxysteroid Dehydrogenases, 3
|
Below are MeSH descriptors whose meaning is more general than "3-Hydroxysteroid Dehydrogenases".
Below are MeSH descriptors whose meaning is more specific than "3-Hydroxysteroid Dehydrogenases".
This graph shows the total number of publications written about "3-Hydroxysteroid Dehydrogenases" by people in this website by year, and whether "3-Hydroxysteroid Dehydrogenases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "3-Hydroxysteroid Dehydrogenases" by people in Profiles.
-
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung. Int J Clin Exp Pathol. 2013; 6(11):2419-29.
-
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int J Clin Exp Pathol. 2012; 5(4):278-89.
-
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer. 2010 Dec 06; 10:672.
-
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol. 2010 Jul 05; 3(6):608-17.
-
Differential expression of type 2 3a/type 5 17ß-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int J Clin Exp Pathol. 2010 Mar 25; 3(8):743-54.
-
Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis. Urology. 2010 Jul; 76(1):67-72.
-
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Exp Pathol. 2009 Nov 15; 3(2):147-55.
-
Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system. J Histochem Cytochem. 2008 Sep; 56(9):853-61.
-
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jul 16; 289(1-2):60-6.
-
Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer. 2006 Mar; 13(1):169-80.